For the other five drugs without PharmGKB annotation: (1) The non-peptidic drug aliskiren could interact with the catalytic site of SARS-CoV-2 main protease and interfere with the viral function [65]; (2) argatroban is a trypsin-like serine protease, which has potential therapeutic benefits in COVID-19 patients via its antithrombotic, anti-inflammatory, and antiviral effects [66]; and (3) bicalutamide is an antiandrogen therapy for male prostate cancer, which was used to tackle the viral entry via regulating TMPRSS2. Here, TMPRSS2 is linked to prostate carcinoma.